Core Insights - The medical color Doppler ultrasound equipment is a crucial imaging device used for various examinations in fields such as abdominal, cardiac, vascular, and obstetrics and gynecology [2] Market Overview - The color Doppler ultrasound category dominates the procurement of ultrasound imaging diagnostic devices, with a procurement quantity of 9,490 units from January to August 2025, accounting for 80.49% of the total quantity and 85.31% of the total value [3] - The domestic color ultrasound market is characterized by a "dual leader" pattern, with Mindray Medical and Kaidi Medical leading the domestic sector, while high-end fields remain dominated by imported brands like GE and Philips [3][11] - The domestic ultrasound market is expected to grow to 17.1 billion yuan by 2026, with a compound annual growth rate of 10.5% from 2021 to 2026 [7] Competitive Landscape - Mindray Medical holds the largest market share at approximately 25.49% for color Doppler ultrasound diagnostic devices, while Kaidi Medical has a market share of about 7.11% [11] - Imported brands still dominate high-end specialized ultrasound fields, but domestic brands are gaining ground in portable and mid-to-low-end markets [11] - The procurement of ultrasound devices in tertiary and above medical institutions accounted for 40.51% of the total quantity and 52.49% of the total value, with a median price of 1.0838 million yuan [7] Technological Trends - The development of ultrasound technology is moving towards 3D/4D imaging, AI-assisted diagnosis, and portability, expanding application scenarios from traditional departments to emergency, grassroots, and mobile medical fields [3] - Future ultrasound devices will integrate AI technology for automatic identification of lesions, quantitative data analysis, and intelligent diagnostic suggestions, enhancing diagnostic efficiency and accuracy [17] - The trend towards portable and wearable ultrasound devices is expected to facilitate quick examinations in emergency and grassroots medical settings [18] Policy and Economic Drivers - The development of medical ultrasound is influenced by various policies and macroeconomic factors, including significant support for equipment updates and grassroots popularization [4] - Recent capital market activities show a trend of leading companies going public and capital focusing on specialized investments, with notable events such as the successful IPO of Super Research Co. and significant funding rounds for other key players [4][6] Industry Chain - The upstream of the medical ultrasound equipment industry consists of mature markets for electronic components, ceramics, and structural parts, with high-end components like imaging chips primarily imported [13] - Midstream companies include large domestic and multinational manufacturers, while downstream users have diverse needs based on the level of medical institutions, with a focus on reliability, ease of use, and after-sales service [13][16]

Core Viewpoint - The article highlights the recent completion of a multi-million yuan Pre-A round financing by Maikesi Medical Technology, aimed at advancing product development and clinical registration in the vascular emergency and life support sector, thereby strengthening its leading position in domestic production [2]. Industry Background - The incidence of critical conditions such as cardiogenic shock and aortic hemorrhage is on the rise, with emergency and circulatory support equipment heavily reliant on imports. The aging population and increasing burden of cardiovascular diseases necessitate effective restoration of circulatory function within the "golden rescue time" [3]. - Internationally, life support equipment represented by VAD and REBOA is gaining attention in critical care and pre-hospital emergency fields. However, existing imported products face issues like high costs and significant risks, making domestic alternatives essential for industry upgrades [3]. Company Introduction - Established in 2023 and headquartered in Shaoxing, Maikesi Medical is one of the few companies in China focusing on the entire chain of "intervention + emergency + service" for life support devices. The core team comprises experts from cardiovascular intervention, mechanical design, and emergency medicine [6]. - Since its inception, the company has aimed to develop a comprehensive technology and service system, focusing on high-risk PCI, cardiogenic shock, trauma, and pre-hospital emergency scenarios, with a product pipeline that combines proprietary intellectual property and mass production capabilities [6]. Product Introduction - Maikesi Medical has developed three core products: 1. **PulseVAD®**: A catheter-based artificial heart system with a diameter of less than 14Fr, reducing vascular damage and limb ischemia risks. It operates in a bionic pulsatile mode, providing effective blood flow support [9]. 2. **Mcsreboa®**: A resuscitative aortic occlusion balloon that integrates ultrasound guidance and automatic inflation technology, enhancing success rates in emergency situations [10]. 3. **Smartpress™**: An intelligent CPR device that ensures stable and precise chest compressions, improving resuscitation quality and neurological recovery rates [11]. - This product combination creates a complete closed-loop from intervention support to emergency resuscitation, addressing critical treatment scenarios [11]. Financing Purpose - The recent financing will focus on: - Advancing clinical registration and certification for core products - Establishing high-standard production lines and quality systems - Strengthening market education and clinical training systems - Promoting collaboration between pre-hospital emergency, intensive care, and intervention centers [12]. - The company plans to complete core product registrations and achieve mass production within two years, while also initiating overseas registration and collaboration processes to build an internationally competitive life support technology platform [12].

Company Overview - Dunbo Medical, established in 2018 and headquartered in Xi'an, Shaanxi Province, is a high-tech company focused on the research and production of Class III active implantable medical devices [26] - The company has developed key medical and semiconductor technologies, including proprietary mixed-signal chips, hardware circuits, software applications, and structural materials [26] - Dunbo Medical has completed four rounds of financing to support its growth and product development [26] Product Highlights - Dunbo Medical's core product is a leadless cardiac pacemaker, which integrates the pulse generator and pacing electrode into a compact capsule that can be directly implanted into the heart [12][14] - The leadless pacemaker has advantages such as a smaller size (only 0.8cc), ease of use, and enhanced safety, eliminating risks associated with lead damage and pocket infections [10][14] - The product's design allows for a significant reduction in complications compared to traditional pacemakers, which rely on leads that can cause infections and displacements [8][10] Market Context - The prevalence of heart failure in China is increasing, with approximately 13.7 million patients aged 35 and older, and an annual increase of around 3 million new cases [15] - The cardiac pacemaker market in China is projected to reach 6.8 billion yuan by 2024, with imported products holding a market share of 89%, indicating a significant opportunity for domestic alternatives [15] - Despite the absence of successful domestic CRT products, there have been notable advancements in other innovative devices for heart failure treatment, such as left ventricular assist devices and cardiac contractility modulation devices [15][16][24] Innovations in Heart Failure Treatment - The left ventricular assist device (LVAD) market is maturing, with four domestic systems approved for sale, each offering unique market advantages [16] - The D-shant atrial shunt device has entered the "national innovative medical device" green channel and is undergoing clinical trials, positioning it competitively against international players [22][23] - The cardiac contractility modulation (CCM) device, developed by Lepu Medical, has passed the special review application and is expected to receive approval soon, marking a significant milestone for domestic innovation in heart failure treatment [24]